Latest Information Update: 31 Aug 2007
At a glance
- Originator Phytopharm
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Burns
Most Recent Events
- 12 Feb 1998 Phase-II clinical trials for Burns in United Kingdom (Topical)
- 29 Jan 1998 Phase-I clinical trials for Burns in United Kingdom (Topical)